how to optimize your safety pharmacology studies
LEARN HOW TO OPTIMIZE YOUR SAFETY PHARMACOLOGY STUDIES
Safety Pharmacology studies play a vital role in helping evaluate the risk of adverse physiological effects posed by new pharmaceutical products and are a required and essential part of most IND-enabling drug safety programs. Given their importance in drug development, some Sponsors also supplement their discovery and early development research with exploratory Safety Pharmacology studies to help enable critical project decisions.
On July 8, Sinclair Research and CorDynamics presented “How to Optimize Your Safety Pharmacology Studies.”
Presented by Dr. Michael R. Gralinski, this webinar will explore the critical role that safety pharmacology studies play in the drug approval process, as well as how to improve your cardiovascular, CNS, respiratory, and ion channel studies to avoid potentially catastrophic delays in your development timeline.
In our webinar, Sinclair and CorDynamics will help you learn:
- How to optimize the design of your safety pharmacology studies
- Challenges you might face regarding environment, species selection, study design, instrumentation, and data analysis
- What to look for when selecting the right CRO partner for your Safety Pharmacology studies
ABOUT THE PRESENTER:
Dr. Michael R. Gralinski is Chief Executive Officer and Co-founder of CorDynamics, a cardiovascular contract research organization based in Chicago. Dr. Gralinski has extensive experience in pharmaceutical development, including product safety, toxicology and safety pharmacology. He is a Past-President of the Safety Pharmacology Society and holds a B.S. in Pharmacology and Toxicology from the University of Wisconsin-Madison and a Ph.D. in Pharmacology (Cardiovascular) from the University of Michigan.